CV Sciences, Inc. (CVSI): Capital Expenditures
$109.0K
Year ended 2025-12-31
$30.0K
Trailing 12 months to 2026-06-30
-36.5%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $109.0K | +505.6% | 2026-03-26, From 2025-01-01 |
| 2024-12-31 | $18.0K | n/a | 2026-03-26, From 2024-01-01 |
| 2023-12-31 | $0 | n/a | 2025-03-27, From 2023-01-01 |
| 2022-12-31 | $0 | -100.0% | 2023-03-30, From 2022-01-01 |
| 2021-12-31 | $35.0K | -96.7% | 2023-03-30, From 2021-01-01 |
| 2020-12-31 | $1.06M | -7.8% | 2022-04-04, From 2020-01-01 |
| 2019-12-31 | $1.15M | n/c | 2021-03-19, From 2019-01-01 |
| 2018-12-31 | $893.0K | +96.7% | 2020-03-30, From 2018-01-01 |
| 2017-12-31 | $454.0K | n/m | 2019-03-12, From 2017-01-01 |
| 2016-12-31 | $17.2K | -84.8% | 2018-03-30, From 2016-01-01 |
| 2015-12-31 | $113.5K | -74.7% | 2017-03-31, From 2015-01-01 |
| 2014-12-31 | $449.2K | +98.2% | 2016-04-14, From 2014-01-01 |
| 2013-12-31 | $226.6K | n/a | 2015-03-31, From 2013-01-01 |
| 2012-12-31 | $0 | n/a | 2014-03-28, From 2012-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| CV Sciences, Inc. (CVSI) | 2025-12-31 | $109.0K | +505.6% |
| Pyxis Oncology, Inc. (PYXS) | 2025-12-31 | $9.0K | -96.2% |
| Arbutus Biopharma Corp (ABUS) | 2025-12-31 | $0 | -100.0% |
| Palatin Technologies Inc (PTN) | 2026-06-30 | $51.3K | n/a |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | $3.37M | n/m |
| Evommune, Inc. (EVMN) | 2025-12-31 | $235.0K | +167.0% |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $1.0K | -91.7% |
| Prelude Therapeutics Inc (PRLD) | 2025-12-31 | $67.0K | -91.2% |
| uniQure N.V. (QURE) | 2025-12-31 | $439.0K | -87.0% |
Compare CVSI, PYXS, ABUS, PTN side by side · Screen every company in Pharmaceutical Preparations ↗